Hospital
Fawcett Memorial Hospital, INC.
Fawcett Memorial Hospital, INC. was paid $3.61M by Medicaid between Jan 2018 and Dec 2024, across 106 billing codes. Its largest line is 99283, emergency room visit (moderate) — 37% of everything it billed.
33Billing provider infoFAWCETT MEMORIAL HOSPITAL, INC.
PORT CHARLOTTE, FL 33952
PORT CHARLOTTE, FL 33952
33aNPI1417901406assigned 05/22/2006
33bProvider typeRehabilitation Hospital Unit
28Total paid$3.61M
24GClaims193,623
24DCodes billed106
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rehabilitation Hospital Unit providers in Florida
Rank by total paid#11 of 11
Median peer was paid$15.92M
This provider vs. median0.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,729 | $148K | |
| 2019 | 41,095 | $614K | |
| 2020 | 29,612 | $315K | |
| 2021 | 36,153 | $559K | |
| 2022 | 39,768 | $864K | |
| 2023 | 19,232 | $693K | |
| 2024incomplete | 7,034 | $412K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 37% | 16,523 | 14,663 | $1.35M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 11,348 | 9,239 | $456K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 9.9% | 7,703 | 1,371 | $358K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.8% | 3,371 | 1,628 | $208K |
| 80053 | Comprehensive metabolic panel | 5.7% | 11,936 | 9,114 | $207K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.1% | 2,365 | 2,165 | $182K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 1,052 | 901 | $131K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 2,351 | 1,768 | $116K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.9% | 993 | 810 | $105K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.2% | 915 | 824 | $81K |
| G0378 | Hospital observation service, per hour | 1.4% | 1,823 | 856 | $50K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,460 | 1,766 | $26K |
94 more codes
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 530 | $22K |
| 87070 | <1% | 1,490 | $21K | |
| 85027 | <1% | 15,351 | $17K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 437 | $17K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 955 | $16K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 782 | $15K |
| 87400 | <1% | 3,931 | $14K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,159 | $13K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,854 | $13K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,099 | $13K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 500 | $12K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 529 | $12K |
| 81001 | <1% | 4,195 | $10K | |
| A9270 | Non-covered item or service | <1% | 7,097 | $10K |
| 85610 | <1% | 5,647 | $9K | |
| 85730 | <1% | 5,171 | $9K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,073 | $9K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,144 | $8K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 56 | $8K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,911 | $7K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,424 | $6K |
| 81003 | <1% | 2,625 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 641 | $5K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,303 | $5K |
| 81025 | <1% | 2,057 | $4K | |
| 97162 | <1% | 114 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,843 | $4K |
| 83735 | <1% | 3,719 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,742 | $3K |
| 84484 | <1% | 5,333 | $3K | |
| 87040 | <1% | 1,473 | $3K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 47 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 327 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,830 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,359 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,834 | $2K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 85 | $2K |
| 86850 | <1% | 606 | $1K | |
| 83690 | <1% | 3,962 | $1K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 21 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 186 | $1K |
| 86900 | <1% | 612 | $1K | |
| 86901 | <1% | 612 | $1K | |
| 87077 | <1% | 620 | $1K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 29 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 955 | $1K |
| 97161 | <1% | 18 | $977.23 | |
| 83880 | <1% | 1,127 | $930.01 | |
| 84100 | <1% | 854 | $913.60 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,631 | $894.45 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 26 | $877.77 |
| 76830 | Ultrasound, transvaginal | <1% | 12 | $775.45 |
| 73562 | <1% | 75 | $689.30 | |
| 74018 | <1% | 15 | $673.23 | |
| 96376 | <1% | 307 | $650.09 | |
| 72131 | <1% | 62 | $625.44 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,950 | $487.54 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 16 | $465.39 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 39 | $458.66 |
| C1769 | Guide wire | <1% | 47 | $458.66 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 430 | $398.27 |
| 87186 | <1% | 359 | $357.73 | |
| 83605 | <1% | 1,392 | $310.77 | |
| 84703 | <1% | 817 | $299.51 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 58 | $291.71 |
| 85379 | <1% | 378 | $274.54 | |
| 73610 | <1% | 47 | $272.54 | |
| 82150 | <1% | 149 | $221.68 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 13 | $220.85 |
| J3490 | Unclassified drugs | <1% | 85 | $192.32 |
| 82550 | <1% | 264 | $178.36 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 417 | $152.47 |
| J7999 | Compounded drug, not otherwise classified | <1% | 45 | $49.20 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 81 | $18.81 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 60 | $15.22 |
| 87807 | <1% | 169 | $8.18 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 123 | $5.04 |
| 87205 | <1% | 40 | $3.04 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 18 | $0.00 |
| 82248 | 0% | 22 | $0.00 | |
| S0028 | Injection, famotidine, 20 mg | 0% | 19 | $0.00 |
| 73630 | 0% | 18 | $0.00 | |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 188 | $0.00 |
| 80076 | 0% | 94 | $0.00 | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 0% | 51 | $0.00 |
| 73130 | 0% | 14 | $0.00 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 37 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 207 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 1,032 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 365 | $0.00 |
| 82803 | 0% | 20 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 267 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 34 | $0.00 |
| 86140 | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHRADER, RICK (CFO)